Menu

Blog

Archive for the ‘biotech/medical’ category: Page 2107

Jan 14, 2019

Would You Zap Your Brain to Improve Your Memory?

Posted by in categories: biotech/medical, neuroscience

Using a few wires and sponges, in ordinary homes around the world, people are trying to hack their own minds. Thanks to a 2002 study that found a link between brain transcranial direct current stimulation and better motor task performance, “do-it-yourself” brain stimulation has become a growing movement among those who want to improve a whole host of cognitive and psychological functions, including language skills, mood and memory.

Scientists are split about the practice: Some say that while brain stimulators might not work as advertised (the ones available to purchase can cost hundreds of dollars), these devices are more-or-less safe. Others think the technique could cause damage, even if done in a controlled, clinical setting. Though “brain hackers” may be disappointed with their own results, their hope about the technology’s potential is rooted in an increasing amount of evidence.

The earliest clinical uses of brain stimulation date back to nearly 2000 years ago, when physician Scribonius Largus recommended the use of electric rayfish to treat headaches and neuralgia. By the 1980s, researchers began designing non-invasive stimulators and brain implants for treating specific diseases. Transcranial direct current stimulation (tDCS) — a non-invasive treatment that uses direct electrical currents to stimulate specific parts of the brain — has been shown, in a few small studies, to purportedly improve language skills, boost memory and strengthen reflexes. Transcranial magnetic stimulation (TMS), another non-invasive procedure, is sometimes used to treat depression. And clinical trials are underway to see if stimulating the brain can treat other medical conditions, such as Parkinson’s.

Continue reading “Would You Zap Your Brain to Improve Your Memory?” »

Jan 14, 2019

A Silver Bullet Against the Brain-Eating Amoeba?

Posted by in categories: biotech/medical, neuroscience

The brain-eating monsters are real enough — they lurk in freshwater ponds in much of the United States. Now scientists may have discovered a new way to kill them.

Minuscule silver particles coated with anti-seizure drugs one day may be adapted to halt Naegleria fowleri, an exceptionally lethal microbe that invades through the sinuses and feeds on human brain tissue.

The research, published in the journal Chemical Neuroscience, showed that repurposing seizure medicines and binding them to silver might kill the amoebae while sparing human cells. Scientists hope the findings will lay an early foundation for a quick cure.

Continue reading “A Silver Bullet Against the Brain-Eating Amoeba?” »

Jan 14, 2019

A Surgeon Reflects On Death, Life And The ‘Incredible Gift’ Of Organ Transplant

Posted by in categories: biotech/medical, health

Fresh Air: Transplant Surgeon Joshua Mezrich On ‘When Death Becomes Life’ : Shots — Health News Joshua Mezrich has performed hundreds of kidney, liver and pancreas transplants. He shares stories from the operating room in his book, When Death Becomes Life.

Read more

Jan 14, 2019

Team finds how error and reward signals are organized within the cerebral cortex

Posted by in categories: biotech/medical, neuroscience

Psychiatrists diagnose people with schizophrenia, ADHD, bipolar disorder and other mental illnesses by spending time with them, looking for the particular behavior symptoms of each. What follows can be a hit-or-miss series of medications and dosages until disruptive behaviors go away.

By deciphering the circuitry of the medial frontal cortex — an area beneath the top of the head — those diagnoses could become much more efficient and precise by allowing physicians to diagnose based on how neurons respond to a simple series of behavior tests.

A Vanderbilt University team recently described how error and reward signals are organized within the cerebral cortex, which is only as thick as a nickel. They say this information could also be significant in drug development by guiding medications to target receptors in particular layers of the cerebral cortex where they will be most effective.

Read more

Jan 14, 2019

UNITY Biotechnologies Selects a New Senolytic Candidate

Posted by in categories: biotech/medical, life extension

Another senolytic drug candidate has entered development at Unity Biotechnologies. The purpose of senolytics is to clear the body of harmful senescent cells, which accumulate with age and encourage age-related diseases to develop.

A new treatment for age-related diseases of the eye

Recently, UNITY Biotechnologies announced the selection of a new lead drug, UBX1967, with the goal of treating a range of age-related diseases of the eye. This is the second drug in the pipeline of this $677 million company. This drug is unique in the world of eye treatment; it targets and destroys senescent cells, making it a senolytic that targets one of the root causes of aging to treat disease.

Continue reading “UNITY Biotechnologies Selects a New Senolytic Candidate” »

Jan 14, 2019

Delivery of 45 Age Reversing Gene Therapies at Once is Under Peer Review

Posted by in categories: biotech/medical, life extension

George Church revealed progress on aging reversal using gene therapies. They have delivered 45 gene therapies to provide aging reversal. They find the combined treatment is effective against obesity, diabetes, osteoarthritis, cardiac damage and kidney disease.

This is the work that Nextbigfuture has been expecting from George’s company Rejuvenate Bio.

Continue reading “Delivery of 45 Age Reversing Gene Therapies at Once is Under Peer Review” »

Jan 13, 2019

Reduced non–rapid eye movement sleep is associated with tau pathology in early Alzheimer’s disease

Posted by in categories: biotech/medical, life extension, neuroscience

In patients with Alzheimer’s disease (AD), amyloid-β (Aβ) plaques and tau protein tangles accumulate in the brain long before the appearance of clinical symptoms. Early intervention is critical for slowing neurodegeneration and disease progression. Therefore, reliable markers of early AD are needed. Lucey et al. analyzed sleep patterns in aging cognitively normal subjects and showed that non–rapid eye movement (NREM) sleep negatively correlated with tau pathology and Aβ deposition in several brain areas. The results show that alterations in NREM sleep may be an early indicator of AD pathology and suggest that noninvasive sleep analysis might be useful for monitoring patients at risk for developing AD.

In Alzheimer’s disease (AD), deposition of insoluble amyloid-β (Aβ) is followed by intracellular aggregation of tau in the neocortex and subsequent neuronal cell loss, synaptic loss, brain atrophy, and cognitive impairment. By the time even the earliest clinical symptoms are detectable, Aβ accumulation is close to reaching its peak and neocortical tau pathology is frequently already present. The period in which AD pathology is accumulating in the absence of cognitive symptoms represents a clinically relevant time window for therapeutic intervention. Sleep is increasingly recognized as a potential marker for AD pathology and future risk of cognitive impairment. Previous studies in animal models and humans have associated decreased non–rapid eye movement (NREM) sleep slow wave activity (SWA) with Aβ deposition. In this study, we analyzed cognitive performance, brain imaging, and cerebrospinal fluid (CSF) AD biomarkers in participants enrolled in longitudinal studies of aging.

Read more

Jan 13, 2019

Fujifilm plans $20M U.S. facility for burgeoning interest in stem cell treatments

Posted by in categories: bioengineering, biotech/medical, genetics

A host of companies are developing regenerative treatments that lean on stem cells. Seeing an opportunity, Japan’s Fujifilm will build a U.S. stem cell manufacturing facility not only for its own efforts but also as a CDMO.

The company said today that its Fujifilm Cellular Dynamics Inc. (FDCI) subsidiary will invest about $21 million to build a facility in Madison, Wisconsin, to “industrialize” induced pluripotent stem cell technologies for its pipeline of regenerative drugs and to manufacture iPS cells for others. It expects the facility to be ready by March 2020.

“To meet the growing demand for FCDI’s iPS cell platform, the state-of-the-art production facility will have a flexible cell culturing design to serve production requirements of both industrial quantities of cells, and small, diverse batches,” Seimi Satake, FCDI CEO, said in a statement. “By combining Fujifilm’s experience gleaned from the intricate process of manufacturing photographic film along with FCDI’s knowledge of cell reprogramming, genetic engineering and cell differentiation, the facility is poised to address the complex manufacturing processes of cell therapies.”

Continue reading “Fujifilm plans $20M U.S. facility for burgeoning interest in stem cell treatments” »

Jan 12, 2019

Doctor double act can help you live healthier for longer in their anti-ageing series for the Mail

Posted by in categories: biotech/medical, life extension, neuroscience

Today in the Mail’s pullout, the twins focus on anti-ageing your brain, and show you simple strategies to give it a boost — from telling you why you’re becoming forgetful to revealing the techniques you can use to improve brain health and function.

Yes, in the ‘spouse’ seat during counselling was Xand, his identical twin and fellow telly doctor.

It’s quite a revelation that these two — both contenders for the title of TV’s sexiest doctor, surely — have a relationship that might require them even to think of counselling.

Continue reading “Doctor double act can help you live healthier for longer in their anti-ageing series for the Mail” »

Jan 12, 2019

Novel Device to Reduce Chemotherapy’s Harmful Side Effects

Posted by in category: biotech/medical

The new device, developed by researchers from the University of California in the US, absorbs excess drugs before they spread throughout the body.

For example, doxorubicin, a chemotherapy drug, kills more tumour cells when given at higher doses. However, most patients cannot tolerate large amounts of the drug because it can cause heart failure, among other side effects.

But using the device, excess doxorubicin can be filtered out from the blood at locations outside of the tumour to reduce the harmful effects of the drug on the healthy cells.

Continue reading “Novel Device to Reduce Chemotherapy’s Harmful Side Effects” »